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The term biomaterial is often used explicitly in the context of 
medical applications, where biodegradability and biocompatibil-
ity play a critical role. In this presentation I will discuss examples 
of various classes of biopolymers with applications that are not 
exclusively related to a use in the body, i.e. for medical purposes. 
Such biopolymers span several families of substances, includ-
ing polysaccharides, polyester, polyphenols, polynucleotides, 
and polypeptides. The huge reservoir of Nature’s biopolymers 
with remarkable characteristics can be expanded by man-made 
technologies, leading to novel combinations of polymers or their 
building blocks in bio-derived polymers. 
The sector of industrial (‘white’) biotechnology includes the 
production and engineering of biopolymers. At Empa we focus 
not only on the engineering of biomaterials for special applica-
tions but also on synthesis and production of novel biomaterials. 
Cellulose makes up 50% of the cell wall of plant cells where it 
provides stability and keeps the plants in shape. The Empa wood 
laboratory explores the production and application of nano-cel-
lulose. By physical treatment natural cellulose fibers are broken 
down into nanofibrils which form networks of polymers with 
high surface area, which are rich in hydrophilic groups. The ad-
vantages of such nanofibrils in materials are their high stability, 
transparency, good barrier functions and their reactivity allowing 
chemical modification. 
In the laboratory for biomaterials we change the characteris-
tics of biopolymers in new combinations with additives in order 
to obtain material characteristics for special purposes, e.g. de-
gradable materials in fields of textiles, packaging, agriculture and 
medicine. We also use biotechnology to produce polyesters and 
polypeptides from bacteria. Bacterial strains are engineered such 
that waste materials can be used for the production of cell mass. 
By applying special fermentation conditions we obtain high cell 
densities and improve yields. In addition we develop environ-
mentally friendly procedures to isolate polyhydroxyalkanoate 
bioplastics in medical grade. The obtained material is used for 
medical but also biological applications. Enzymes involved in 
synthesis, degradation or conversion of biopolymers are cloned, 
produced and engineered in our laboratory. An example is tyrosi-
nase, the key enzyme of melanin biosynthesis, which has further 
applications such as protein immobilization. 
Biopolymers comprise polymeric materials that are either 
bio-based, i.e. made by natural processes from natural sources, 
or that can be degraded by natural processes. In times when pet-
rochemical resources become more limited, or are regarded eco-
logically problematic, these sustainable materials are expected to 
become more and more important and economically competitive.
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Similar to conventional lipids, suitable amphiphilic block 
copolymers may self-assemble in aqueous media to membrane-
like superstructures. The physical properties of these membranes 
can be controlled to a large degree via the chemical constitution, 
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the molecular weight and the hydrophilic-to-hydrophobic block 
length ratio of these polymers. Compared to conventional low 
molar mass building blocks (e.g. lipids), membranes based on 
macromolecular self-assembly not only have the advantage of 
superior stability and toughness, but in addition offer numerous 
possibilities of tailoring physical, chemical and biological prop-
erties since many functions can be implemented simultaneously 
in one single macromolecule.
Moreover, other well-defined functions such as recognition, 
cooperativity, regulation, replication, and catalysis can be intro-
duced by combining these superstructures with suitable function-
al groups from nature, e.g. by incorporation of integral membrane 
proteins into the biomimetic membranes. Recently, we used this 
concept to prepare polymer nanoreactors by encapsulating water-
soluble enzymes inside the aqueous compartments of block copo-
lymer vesicles. Channel proteins were used to selectively control 
the exchange of substrates and products with the environment. 
Immobilized polymer nanoreactors were used as chemically and 
mechanically stable, nanometer-sized compartments to follow 
folding/unfolding of single proteins and to monitor enzymatic 
reactions down to a single nanoreactor scale. Model reactions 
were used to demonstrate the potential of these structures for 
biosensing and the local production of bioactive compounds. In 
addition, these nanoreactors can be targeted to predefined cells. 
After cellular uptake, they retain their function over extended 
times inside the living cells, thus acting as a sort of artificial 
organelle. This opens new ways for controlled drug delivery and 
intracellular sensing.
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